Citius Pharmaceuticals Inc (NASDAQ: CTXR), a specialty pharmaceutical company, announced on Friday that it has named Dr Lawrence Mermel as a new member to the Scientific Advisory Board.

Dr Mermel is professor of Medicine at the Warren Alpert Medical School of Brown University. He joins Dr Isaam Raad, the chair of MD Anderson Cancer Center's Department of Infectious Diseases (also chairman of the Citius Scientific Advisory Board), and Dr Mark Rupp, professor and chief of the Division of Infectious Diseases at the University of Nebraska Medical Center. All of these individuals are recognised as opinion leaders in bloodstream infections. Each has led research in Catheter Related Bloodstream Infections, authored important scientific and clinical papers, led nationally recognised organisations, and contributed to the treatment guidelines followed by physicians globally. The Advisory Board will be counselling the firm on its development programs, particularly the anti-infective portfolio, which includes the company's lead technology, Mino-Lok.

Myron Holubiak, CEO of Citius, said, 'We are honoured to have been able to empanel such a prestigious group of experts to help guide us in the development of Mino-Lok and other infectious disease products. All of our SAB members are recognised opinion leaders who developed our understanding of these diseases, how to prevent them, and how to treat them. These world class Infectious Disease leaders will advise us in driving the company's current Phase 3 study forward and offer valuable perspective as we advance our anti-infective development programs.'